Apotex Health Statistics
Total Valuation
Apotex Health has a market cap or net worth of CAD 9.55 billion. The enterprise value is 12.41 billion.
Important Dates
The last earnings date was Thursday, November 12, 2026.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | Dec 14, 2026 |
Share Statistics
Apotex Health has 229.03 million shares outstanding. The number of shares has increased by 14.12% in one year.
| Current Share Class | 229.03M |
| Shares Outstanding | 229.03M |
| Shares Change (YoY) | +14.12% |
| Shares Change (QoQ) | +21.40% |
| Owned by Insiders (%) | 0.14% |
| Owned by Institutions (%) | 10.32% |
| Float | 228.71M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 18.61 |
| PS Ratio | 2.98 |
| PB Ratio | 22.13 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 47.18 |
| P/OCF Ratio | 29.06 |
| PEG Ratio | 0.70 |
Financial Ratio History Enterprise Valuation
The stock's EV/EBITDA ratio is 15.53, with an EV/FCF ratio of 61.32.
| EV / Earnings | n/a |
| EV / Sales | 3.87 |
| EV / EBITDA | 15.53 |
| EV / EBIT | 19.94 |
| EV / FCF | 61.32 |
Financial Position
The company has a current ratio of 1.76, with a Debt / Equity ratio of 6.81.
| Current Ratio | 1.76 |
| Quick Ratio | 0.83 |
| Debt / Equity | 6.81 |
| Debt / EBITDA | 3.68 |
| Debt / FCF | 14.52 |
| Interest Coverage | 2.60 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | -2.04% |
| Return on Capital Employed (ROCE) | 17.90% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 534,319 |
| Profits Per Employee | -1,561 |
| Employee Count | 6,000 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Apotex Health has paid 98.72 million in taxes.
| Income Tax | 98.72M |
| Effective Tax Rate | 110.48% |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 33.76 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 81.86 |
| Average Volume (20 Days) | 429,033 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Apotex Health had revenue of CAD 3.21 billion and -9.37 million in losses. Loss per share was -0.07.
| Revenue | 3.21B |
| Gross Profit | 1.64B |
| Operating Income | 622.60M |
| Pretax Income | 89.35M |
| Net Income | -9.37M |
| EBITDA | 767.34M |
| EBIT | 622.60M |
| Loss Per Share | -0.07 |
Full Income Statement Balance Sheet
The company has 77.96 million in cash and 2.94 billion in debt, with a net cash position of -2.86 billion or -12.49 per share.
| Cash & Cash Equivalents | 77.96M |
| Total Debt | 2.94B |
| Net Cash | -2.86B |
| Net Cash Per Share | -12.49 |
| Equity (Book Value) | 431.47M |
| Book Value Per Share | 1.88 |
| Working Capital | 933.56M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was 328.60 million and capital expenditures -126.18 million, giving a free cash flow of 202.42 million.
| Operating Cash Flow | 328.60M |
| Capital Expenditures | -126.18M |
| Depreciation & Amortization | 144.74M |
| Net Borrowing | -949.46M |
| Free Cash Flow | 202.42M |
| FCF Per Share | 0.88 |
Full Cash Flow Statement Margins
Gross margin is 51.03%, with operating and profit margins of 19.42% and -0.29%.
| Gross Margin | 51.03% |
| Operating Margin | 19.42% |
| Pretax Margin | 2.79% |
| Profit Margin | -0.29% |
| EBITDA Margin | 23.94% |
| EBIT Margin | 19.42% |
| FCF Margin | 6.31% |
Dividends & Yields
This stock pays an annual dividend of 0.20, which amounts to a dividend yield of 0.48%.
| Dividend Per Share | 0.20 |
| Dividend Yield | 0.48% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | 12.45% |
| Buyback Yield | -14.12% |
| Shareholder Yield | -13.64% |
| Earnings Yield | -0.16% |
| FCF Yield | 2.12% |
Dividend Details Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Analyst Forecast
The average price target for Apotex Health is 44.13, which is 5.83% higher than the current price. The consensus rating is "Buy".
| Price Target | 44.13 |
| Price Target Difference | 5.83% |
| Analyst Consensus | Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | 5.40% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Apotex Health has an Altman Z-Score of 2.17 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.17 |
| Piotroski F-Score | 3 |